Live Breaking News & Updates on Fate Therapeutics Daily

Stay updated with breaking news from Fate therapeutics daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Fate Therapeutics (NASDAQ:FATE) Shares Down 6.4%

Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating)’s share price fell 6.4% during trading on Thursday . The company traded as low as $5.05 and last traded at $5.12. 514,360 shares traded hands during trading, a decline of 84% from the average session volume of 3,163,753 shares. The stock had previously closed at $5.47. Analysts Set […] ....

Piper Sandler , Envestnet Asset Management Inc , Hightower Advisors , Securities Exchange Commission , Financial Services Group Inc , Ef Hutton Acquisition Co , Raymond James Associates , Advisor Group , Cantor Fitzgerald , Fate Therapeutics Company Profile , Fate Therapeutics Inc , Redmile Group Llc , Fate Therapeutics , Get Rating , Director Redmile Group , Exchange Commission , Asset Management , Tower Advisors , Services Group , Fate Therapeutics Daily , Nasdaq Fate ,

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $13.19 Average PT from Brokerages

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have been given an average rating of “Hold” by the twenty-two ratings firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating on […] ....

Piper Sandler , Fate Therapeutics Inc , Cantor Fitzgerald , Securities Exchange Commission , Wells Fargo Company , Redmile Group Llc , Fate Therapeutics Company Profile , Financial Services Group Inc , Royal Bank , Ef Hutton Acquisition Co , Fate Therapeutics , Get Rating , Director Redmile Group , Exchange Commission , Pension Plan Investment Board , Services Group , Two Sigma Advisers , Sigma Advisers , Fate Therapeutics Daily , Nasdaq Fate ,

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have been given a consensus rating of “Hold” by the twenty-three research firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and five have issued a buy recommendation on the […] ....

Alexander Rives , Philip Beachy , Michael Rudnicki , Stifel Nicolaus , David Scadden , Scott Wolchko , Piper Sandler , Rudolf Jaenisch , Leonard Zon , Ef Hutton Acquisition Co , Fate Therapeutics Inc , Advisor Group , Envestnet Asset Management Inc , Securities Exchange Commission , Redmile Group Llc , Fate Therapeutics Company Profile , Raymond James Associates , Cantor Fitzgerald , Hightower Advisors , Financial Services Group Inc , Fate Therapeutics , Get Rating , Director Redmile Group , Exchange Commission , Asset Management , Tower Advisors ,

Essential Properties Realty Trust, Inc. (NYSE:EPRT) Receives $25.93 Consensus PT from Analysts

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its target price lowered by Stifel Nicolaus from $5.30 to $5.00 in a research report sent to investors on Thursday, The Fly reports. Several other analysts also recently weighed in on the stock. HC Wainwright downgraded shares of Fate Therapeutics from a buy rating to a neutral rating […] ....

Rudolf Jaenisch , Philip Beachy , Stifel Nicolaus , Michael Rudnicki , Leonard Zon , Alexander Rives , Scott Wolchko , David Scadden , Blackrock Inc , Pricet Rowe Associates Inc , Vanguard Group Inc , Wells Fargo Company , Fate Therapeutics Inc , Redmile Group Llc , Fate Therapeutics , Get Rating , Director Redmile Group , Street Corp , Capital World Investors , World Investors , Sheng Ding , Fate Therapeutics Daily , Nasdaq Fate , Lower Price Target ,

Cantor Fitzgerald Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $5.00

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its target price lowered by Cantor Fitzgerald from $8.00 to $5.00 in a report published on Thursday, The Fly reports. FATE has been the topic of a number of other reports. Morgan Stanley reduced their price objective on shares of Fate Therapeutics from $35.00 to $8.00 and set […] ....

United States , Philip Beachy , Michael Rudnicki , Alexander Rives , Scott Wolchko , David Scadden , Leonard Zon , Rudolf Jaenisch , Morgan Stanley , Cantor Fitzgerald , Blackrock Inc , Fate Therapeutics Inc , Redmile Group Llc , Vanguard Group Inc , Securities Exchange Commission , Pricet Rowe Associates Inc , Fate Therapeutics , Get Rating , Truist Financial , Therapeutics Stock Down , Director Redmile Group , Exchange Commission , Street Corp , Capital World Investors , World Investors , Sheng Ding ,